Resistance to trastuzumab remains a major obstacle in HER2‐overexpressing breast cancer
treatment. miR‐200c is important for many functions in cancer stem cells (CSCs), including …

It has been found that microRNAs (miRNAs) play a key role in drug resistance. The purpose
of the current study was to investigate the function of miR-182 in trastuzumab resistance in …

MicroRNAs (miRNAs) have been found to play a key role in drug resistance. In the current
study, we aimed to explore the potential role of miR‐126 in trastuzumab resistance in breast …

Background Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab
(Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast …

A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab.
Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators …

Objectives miR‐99a has been reported to function as a tumour suppressor in breast cancer.
However, its role in the regulation of breast cancer stem cell (CSC) phenotype has up to now …

The EGFR/HER2 signaling network is an effective therapeutic target for HER2-positive
cancers, which are known for their aggressive biological course. Evidence indicates that the …

Background/Aims: Trastuzumab is an important treatment used for patients with Her-2-
positive breast cancer, but an increasing incidence of trastuzumab resistance has been …

Trastuzumab (Herceptin) has been widely used in breast cancer treatment. However, the
majority of cancers that initially respond to trastuzumab begin to progress again within 1 …

Resistance to chemotherapy is a major obstacle for the effective treatment of breast cancer
and is partially due to the presence of drug resistant stem cell‐like side population (SP) …